Table 1.
Descriptive characteristic of study sample
| Thailand | Brazil | Zambia | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Heterosexual men |
MSM | Heterosexual women |
Heterosexual men |
MSM | Heterosexual women |
Heterosexual men |
Heterosexual women |
||
| Total N enrolled | 100 | 100 | 100 | 64 | 100 | 99 | 86 | 100 | 749 |
| N taken ART in the last 3 months | 98/100 (98 %) | 96/100 (96 %) | 96/100 (96 %) | 53/64 (83 %) | 59/100 (59 %) | 70/99 (71 %) | 83/86 (97 %) | 88/100 (88 %) | 643/749 (86 %) |
| ART adherence (last 3 months)a | |||||||||
| Missing | 0/98 (0 %) | 0/96 (0 %) | 0/96 (0 %) | 0/53 (0 %) | 1/59 (2 %) | 0/70 (0 %) | 0/83 (0 %) | 0/88 (0 %) | 1/643 (< 1 %) |
| Very poor | 1/98 (1 %) | 0/96 (0 %) | 1/96 (1 %) | 1/53 (2 %) | 0/59 (0 %) | 3/70 (4 %) | 1/83 (1 %) | 0/88 (0 %) | 7/643 (1 %) |
| Poor | 1/98 (1 %) | 0/96 (0 %) | 2/96 (2 %) | 1/53 (2 %) | 1/59 (2 %) | 1/70 (1 %) | 1/83 (1 %) | 0/88 (0 %) | 7/643 (1 %) |
| Fair | 19/98 (19 %) | 10/96 (10 %) | 13/96 (14 %) | 4/53 (8 %) | 9/59 (15 %) | 9/70 (13 %) | 5/83 (6 %) | 2/88 (2 %) | 71/643 (11 %) |
| Good | 36/98 (37 %) | 41/96 (43 %) | 33/96 (34 %) | 18/53 (34 %) | 14/59 (24 %) | 24/70 (34 %) | 28/83 (34 %) | 32/88 (36 %) | 226/643 (35 %) |
| Very good | 34/98 (35 %) | 40/96 (42 %) | 41/96 (43 %) | 12/53 (23 %) | 14/59 (24 %) | 10/70 (14 %) | 30/83 (36 %) | 33/88 (38 %) | 214/643 (33 %) |
| Excellent | 7/98 (7 %) | 5/96 (5 %) | 6/96 (6 %) | 17/53 (32 %) | 20/59 (34 %) | 23/70 (33 %) | 18/83 (22 %) | 21/88 (24 %) | 117/643 (18 %) |
| Any STI (lab result) | |||||||||
| Missing | 0/100 (0 %) | 0/100 (0 %) | 0/100 (0 %) | 2/64 (3 %) | 3/100 (3 %) | 11/99 (11 %) | 3/86 (3 %) | 3/100 (3 %) | 22/749 (3 %) |
| No | 95/100 (95 %) | 68/100 (68 %) | 93/100 (93 %) | 56/64 (88 %) | 41/100 (41 %) | 79/99 (80 %) | 78/86 (91 %) | 87/100 (87 %) | 597/749 (80 %) |
| Yes | 5/100 (5 %) | 32/100 (32 %) | 7/100 (7 %) | 6/64 (9 %) | 56/100 (56 %) | 9/99 (9 %) | 5/86 (6 %) | 10/100 (10 %) | 130/749 (17 %) |
| N with VL available | 85/100 (85 %) | 85/100 (85 %) | 82/100 (82 %) | 49/64 (77 %) | 85/100 (85 %) | 89/99 (90 %) | 0/86 (0 %) | 0/100 (0 %) | 475/749 (63 %) |
| Detectable VL | 13/85 (15 %) | 11/85 (13 %) | 8/82 (10 %) | 12/49 (24 %) | 40/85 (47 %) | 31/89 (35 %) | 0/0 (0 %) | 0/0 (0 %) | 115/475 (24 %) |
| N qualified for swiss infectious criteria | 84/100 (84 %) | 84/100 (84 %) | 82/100 (82 %) | 47/64 (73 %) | 82/100 (82 %) | 78/99 (79 %) | 0/86 (0 %) | 0/100 (0 %) | 457/749 (61 %) |
| Met Swiss criteria for Infectiousness | |||||||||
| No | 66/84 (79 %) | 47/84 (56 %) | 68/82 (83 %) | 31/47 (66 %) | 18/82 (22 %) | 45/78 (58 %) | 0/0 (0 %) | 0/0 (0 %) | 275/457 (60 %) |
| Yes | 18/84 (21 %) | 37/84 (44 %) | 14/82 (17 %) | 16/47 (34 %) | 64/82 (78 %) | 33/78 (42 %) | 0/0 (0 %) | 0/0 (0 %) | 182/457 (40 %) |
| With unprotected sex | 12/18 (67 %) | 24/37 (65 %) | 13/14 (93 %) | 11/16 (69 %) | 44/64 (69 %) | 29/33 (88 %) | 0/0 (0 %) | 0/0 (0 %) | 133/182 (73 %) |
| Unprotected sex with HIV-/unk partners | |||||||||
| Missing | 1/100 (1 %) | 3/100 (3 %) | 0/100 (0 %) | 0/64 (0 %) | 0/100 (0 %) | 0/99 (0 %) | 9/86 (10 %) | 4/100 (4 %) | 17/749 (2 %) |
| No | 33/100 (33 %) | 35/100 (35 %) | 8/100 (8 %) | 28/64 (44 %) | 23/100 (23 %) | 21/99 (21 %) | 12/86 (14 %) | 5/100 (5 %) | 165/749 (22 %) |
| Yes | 66/100 (66 %) | 62/100 (62 %) | 92/100 (92 %) | 36/64 (56 %) | 77/100 (77 %) | 78/99 (79 %) | 65/86 (76 %) | 91/100 (91 %) | 567/749 (76 %) |
| Met criteria for amplified HIV transmission risk | |||||||||
| No | 72/84 (86 %) | 60/84 (71 %) | 69/82 (84 %) | 36/47 (77 %) | 38/82 (46 %) | 49/78 (63 %) | 0/0 (0 %) | 0/0 (0 %) | 324/457 (71 %) |
| Yes | 12/84 (14 %) | 24/84 (29 %) | 13/82 (16 %) | 11/47 (23 %) | 44/82 (54 %) | 29/78 (37 %) | 0/0 (0 %) | 0/0 (0 %) | 133/457 (29 %) |
| Unprotected sex acts in past 3 months with HIV-unknown partners (among those who Qualified for Swiss Criteria) | |||||||||
| Median | 2 | 2 | 3 | 4 | 4 | 4 | – | – | 3 |
| 25th, 75th %tile | 0, 4 | 0, 10 | 2, 5 | 1, 18 | 1, 19 | 1, 28 | – | – | 0, 15 |
| Min, max | 0, 45 | 0, 64 | 0, 40 | 0, 30 | 0, 750 | 0, 2520 | – | – | 0, 2520 |
| Social support score | |||||||||
| Median | 35 | 34 | 35 | 33 | 34 | 33 | 36 | 36 | 35 |
| 25th, 75th %tile | 32, 36 | 30, 36 | 30, 36 | 28, 36 | 29, 38 | 29, 38 | 33, 38 | 33, 37 | 30, 36 |
| Min, max | 24, 45 | 19, 45 | 23, 45 | 18, 45 | 14, 45 | 11, 45 | 13, 45 | 23, 45 | 11, 45 |
| CESD score | |||||||||
| Median | 10 | 11 | 11 | 13 | 16 | 16 | 6 | 9 | 11 |
| 25th, 75th %tile | 6, 15 | 6, 18 | 6, 19 | 6, 25 | 8, 31 | 8, 32 | 2, 13 | 4, 16 | 6, 20 |
| Min, max | 2, 32 | 1, 37 | 0, 40 | 0, 51 | 1, 46 | 0, 53 | 0, 32 | 0, 40 | 0, 53 |
| HIV disclosure (factor 1) | |||||||||
| Median | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 25th, 75th %tile | 3, 3 | 3, 3 | 3, 3 | 3, 3 | 2, 3 | 3, 3 | 3, 3 | 3, 3 | 3, 3 |
| Min, max | 2, 4 | 1, 4 | 2, 4 | 1, 4 | 1, 4 | 2, 4 | 2, 4 | 1, 4 | 1, 4 |
| Fear of consequences of disclosure (Factor 2) | |||||||||
| Median | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 3 |
| 25th, 75th %tile | 2, 3 | 2, 3 | 2, 3 | 2, 3 | 3, 3 | 3, 3 | 2, 3 | 2, 3 | 2, 3 |
| Min, max | 1, 4 | 2, 4 | 1, 4 | 1, 4 | 2, 4 | 1, 4 | 1, 4 | 1, 3 | 1, 4 |
| ACTG SF-21 subscales | |||||||||
| General health perception | |||||||||
| Median | 75 | 71 | 67 | 58 | 58 | 58 | 75 | 75 | 67 |
| 25th, 75th %tile | 58, 75 | 50, 75 | 50, 75 | 42, 83 | 33, 83 | 33, 83 | 58, 75 | 50, 75 | 50, 75 |
| Min, max | 8, 100 | 8, 100 | 0, 100 | 0, 100 | 0, 100 | 0, 100 | 25, 100 | 8, 100 | 0, 100 |
| Physical functioning | |||||||||
| Median | 100 | 100 | 100 | 88 | 100 | 88 | 100 | 100 | 100 |
| 25th, 75th %tile | 100, 100 | 88, 100 | 88, 100 | 63, 100 | 75, 100 | 63, 100 | 88, 100 | 88, 100 | 88, 100 |
| Min, max | 38, 100 | 50, 100 | 25, 100 | 13, 100 | 25, 100 | 0, 100 | 50, 100 | 0, 100 | 0, 100 |
| Role functioning | |||||||||
| Median | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| 25th, 75th %tile | 100, 100 | 100, 100 | 100, 100 | 50, 100 | 50, 100 | 75, 100 | 100, 100 | 100, 100 | 100, 100 |
| Min, max | 50, 100 | 50, 100 | 0, 100 | 0, 100 | 0, 100 | 0, 100 | 25, 100 | 25, 100 | 0, 100 |
| Social functioning | |||||||||
| Median | 89 | 89 | 100 | 100 | 89 | 100 | 100 | 100 | 94 |
| 25th, 75th %tile | 78, 100 | 78, 100 | 78, 100 | 72, 100 | 67, 100 | 67, 100 | 78, 100 | 67, 100 | 78, 100 |
| Min, max | 11, 100 | 33, 100 | 33, 100 | 0, 100 | 0, 100 | 11, 100 | 22, 100 | 33, 100 | 0, 100 |
| Cognitive functioning | |||||||||
| Median | 87 | 80 | 80 | 87 | 80 | 80 | 97 | 87 | 87 |
| 25th, 75th %tile | 73, 100 | 67, 87 | 67, 87 | 70, 100 | 73, 100 | 67, 93 | 87, 100 | 73, 100 | 73, 100 |
| Min, max | 40, 100 | 27, 100 | 27, 100 | 0, 100 | 7, 100 | 0, 100 | 47, 100 | 33, 100 | 0, 100 |
| Pain | |||||||||
| Median | 89 | 89 | 78 | 72 | 67 | 56 | 100 | 89 | 78 |
| 25th, 75th %tile | 67, 100 | 67, 100 | 67, 100 | 33, 100 | 44, 100 | 44, 78 | 67, 100 | 67, 100 | 56, 100 |
| Min, max | 44, 100 | 0, 100 | 22, 100 | 11, 100 | 0, 100 | 0, 100 | 22, 100 | 11, 100 | 0, 100 |
| Mental health | |||||||||
| Median | 67 | 67 | 60 | 60 | 53 | 53 | 67 | 60 | 60 |
| 25th, 75th %tile | 60, 67 | 60, 67 | 53, 67 | 47, 67 | 40, 67 | 40, 67 | 53, 67 | 47, 67 | 47, 67 |
| Min, max | 33, 87 | 33, 80 | 20, 93 | 33, 100 | 7, 100 | 0, 87 | 27, 80 | 13, 73 | 0, 100 |
| Energy/fatigue | |||||||||
| Median | 80 | 80 | 80 | 70 | 70 | 70 | 90 | 80 | 80 |
| 25th, 75th %tile | 70, 90 | 60, 90 | 60, 100 | 40, 95 | 40, 100 | 50, 90 | 60, 100 | 50, 100 | 60, 100 |
| Min, max | 40, 100 | 40, 100 | 0, 100 | 0, 100 | 0, 100 | 0, 100 | 20, 100 | 0, 100 | 0, 100 |
a
ART adherence was assessed among individuals who reported being on ART in past three months